Clinical trial · Interventional
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
NCT05988970CI-TRIAL-00101740SLEEP_CTCcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC. 27 patients will be included in the study and will be followed for 12 months. For each included patient, blood samples will be collected before the anticancer treatment initiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples will be collected at two times before the treatment initiation: | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with Non- Small Cell Lung Cancer - NSCLC
- interventionNames
- Other: Blood samples will be collected at two times before the treatment initiation:
Primary outcomes (1)
- measure
- Presence of CTCs detected with the CellSearch technique.
- timeFrame
- 12 months after the end of inclusions
Secondary outcomes (4)
- measure
- Quantification of CTCs by the CellSearch technique and expressed in number of cells / millilitre of blood.
- timeFrame
- 12 months after the end of inclusions
- measure
- Quantification of CTCs by the ParSortix technique and expressed in number of cells / millilitre of blood.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with histologically confirmed advanced NSCLC (inoperable stage 3 or 4) 2. Patient aged ≥ 18 years 3. Life expectancy \> 3 months 4. Patient naïve to treatment for NSCLC 5. Patient hospitalized at least one night for initiation of specific treatment (chemotherapy, radiotherapy, surgery, other...) 6. Patient with no other active cancer. Cancer history accepted if more than 3 years old and considered cured. 7. Patient affiliated to a Social Security scheme in France. 8. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: 1. Small-cell cancer or cancer with a majority small-cell contingent 2. Patient previously treated for NSCLC 3. Outpatient 4. Patient with active pathology such as sepsis or uncontrolled inflammatory syndrome 5. Any pathology contraindicating the sample collection procedures required by the study. 6. Pregnant or breast-feeding women. 7. Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical follow-up and/or procedures stipulated in the study protocol. 8. Patients deprived of their liberty or under legal protection (guardianship, legal protection).
References
Publications (0)
Data not yet available
No reference posted for this study.